← Back to headlines
Ligand Stock Resumed at Buy by Citi Following XOMA Royalty Acquisition
Citi has resumed its 'buy' rating for Ligand Pharmaceuticals stock, citing the company's recent acquisition of XOMA Royalty as a key factor.
21 Jul, 19:35 — 21 Jul, 19:35
Sources
Showing 1 of 1 sources
